Pre-made Plonmarlimab benchmark antibody ( Whole mAb, anti-CSF2 therapeutic antibody, Anti-CSF/GMCSF Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Plonmarlimab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Plonmarlimab [previously TJM 2 (TJ 003234)] is a first-in-class, humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting neutralise.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-453-1mg	1mg	3090	30%	2163

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Plonmarlimab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody
INN Name	Plonmarlimab
Target	CSF2
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II/III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2020
Year Recommended	na
Companies	I-Mab Biopharma
Conditions Approved	na
Conditions Active	Rheumatoid arthritis;COVID-19;Osteoarthritis
Conditions Discontinued	na
Development Tech	na